New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Authors
Keywords
Homozygous familial hypercholesterolemia, PCSK9, Lomitapide, Inclisiran, Gene therapy, Gene-editing, Angiopoietin-like 3, Low-density lipoprotein cholesterol
Journal
Heart Failure Clinics
Volume 18, Issue 1, Pages 177-188
Publisher
Elsevier BV
Online
2021-10-22
DOI
10.1016/j.hfc.2021.07.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins
- (2020) Hanna Ruhanen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition
- (2020) Arturo Cesaro et al. BIOFACTORS
- Familial combined hypolipidemia
- (2020) Marcello Arca et al. CURRENT OPINION IN LIPIDOLOGY
- Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Evidence for improved survival with treatment of homozygous familial hypercholesterolemia
- (2020) Alexandre M. Bélanger et al. CURRENT OPINION IN LIPIDOLOGY
- Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
- (2020) Dirk J. Blom et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a)
- (2020) Arturo Cesaro et al. Journal of Cardiovascular Medicine
- Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)
- (2020) James A. Underberg et al. Journal of Clinical Lipidology
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
- (2019) Daniel Gaudet et al. AMERICAN JOURNAL OF CARDIOLOGY
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia
- (2019) Huan Zhao et al. CIRCULATION
- Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
- (2019) Ye-Xuan Cao et al. Journal of Translational Medicine
- Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies
- (2018) Felice Gragnano et al. ATHEROSCLEROSIS
- Inclisiran for the treatment of dyslipidemia
- (2018) Toshiyuki Nishikido et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lomitapide in homozygous familial hypercholesterolemia
- (2018) Simona Sperlongano et al. Journal of Cardiovascular Medicine
- Autosomal Recessive Hypercholesterolemia
- (2018) Laura D’Erasmo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients
- (2017) Felice Gragnano et al. Journal of Cardiovascular Medicine
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis
- (2017) Robert Leipold et al. European Journal of Preventive Cardiology
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- (2017) Frederick J Raal et al. Lancet Diabetes & Endocrinology
- Homozygous autosomal dominant hypercholesterolaemia
- (2015) Barbara Sjouke et al. CURRENT OPINION IN LIPIDOLOGY
- Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
- (2015) Yan Wang et al. JOURNAL OF LIPID RESEARCH
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
- (2014) Barbara Sjouke et al. EUROPEAN HEART JOURNAL
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- The Severe Hypercholesterolemia Phenotype
- (2014) Allan D. Sniderman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- CRISPR-Cas systems for editing, regulating and targeting genomes
- (2014) Jeffry D Sander et al. NATURE BIOTECHNOLOGY
- Familial combined hypolipidemia due to mutations in the ANGPTL3 gene
- (2013) Sebastiano Calandra et al. Clinical Lipidology
- Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
- (2013) Ilenia Minicocci et al. JOURNAL OF LIPID RESEARCH
- Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
- (2012) Stanley T. Crooke et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Guidelines for the Management of Familial Hypercholesterolemia
- (2012) Mariko Harada-Shiba et al. Journal of Atherosclerosis and Thrombosis
- Mutations in theANGPTL3Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization
- (2012) Ilenia Minicocci et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Multiple functions of microsomal triglyceride transfer protein
- (2012) M Mahmood Hussain et al. Nutrition & Metabolism
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
- (2011) Frederick J. Raal et al. CIRCULATION
- Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
- (2011) Anne C. Goldberg et al. Journal of Clinical Lipidology
- Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia
- (2011) Küçükkartallar Tevfik et al. PEDIATRIC TRANSPLANTATION
- Translational Lessons from a Case of Combined Heart and Liver Transplantation for Familial Hypercholesterolemia 20 Years Post-operatively
- (2011) Michael Ibrahim et al. Journal of Cardiovascular Translational Research
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
- (2008) Daniel M. Kolansky et al. AMERICAN JOURNAL OF CARDIOLOGY
- Recommendations for the use of LDL apheresis
- (2008) G.R. Thompson ATHEROSCLEROSIS
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
- (2008) John J.P. Kastelein et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now